北京福元医药股份有限公司关于联苯苄唑溶液获得药品注册证书的公告

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. has received a drug registration certificate for its Benzyl Benzoate solution, which is expected to enhance the company's product line and market competitiveness [1][4]. Drug Registration Certificate Details - The drug registration certificate was issued by the National Medical Products Administration, allowing the production of Benzyl Benzoate solution (1% concentration, 10 mL: 0.1 g) [1]. - The drug is indicated for the treatment of various skin fungal diseases, including tinea pedis, tinea corporis, tinea cruris, and candidiasis [6]. R&D Investment - The total R&D investment for this drug has reached approximately RMB 3.0496 million (unaudited) as of the announcement date [2]. Market Situation for Similar Drugs - According to data from Minet, the sales revenue of Benzyl Benzoate solution in China's three major terminal markets is approximately RMB 375.26 million in 2024. The breakdown is as follows: - Sales in urban public hospitals and county-level public hospitals: RMB 76.55 million - Sales in urban community centers and township health clinics: RMB 41.96 million - Sales in urban pharmacies and online pharmacies: RMB 256.75 million [3]. Impact on the Company - The approval of the drug registration certificate is expected to enrich the company's product line and enhance its market competitiveness. However, the sales performance may be influenced by national policies and market environment changes, leading to significant uncertainty [4].